A Comparison of the Efficacy of Immunomodulatory-Containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis
Conclusion In patients with RRMM who are suitable for an IMiD-containing regimen, DRd has clear advantages in survival and response outcomes over other IMiD-containing regimens. Teaser A systematic review and network meta-analysis were conducted to compare the clinical efficacy of immunomodulatory drug–containing regimens in patients with RRMM. Daratumumab plus lenalidomide and dexamethasone had a significant advantage in improving progression-free survival in patients compared to other immunomodulatory-containing regimens.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Dexamethasone | Leukemia | Lymphoma | Myeloma | Revlimid | Study | Velcade